Hematology Today—April 20, 2026

This week’s Hematology update highlights regulatory progress, early- and late-stage clinical data, expanding cell therapy pipelines, and strategic partnerships across high-need blood cancers.

Dive deeper

💊 Opna Bio, OPN-6602 gets FDA Fast Track in multiple myeloma [1] [US • 15 Apr 2026]

https://www.opnabio.com/opna-bio-announces-fast-track-designation-granted-to-opn-6602-for-the-treatment-of-multiple-myeloma/
Context: OPN-6602 (Opna Bio, dual EP300/CBP inhibitor) is an oral small molecule in Phase 1 for relapsed/refractory multiple myeloma after at least four prior lines.
Key point: FDA granted Fast Track designation to OPN-6602 for relapsed/refractory multiple myeloma.
Implication: Introduces a regulatory advantage that may accelerate development and review.

🧬 Roswell Park, CD83 CAR-T enters clinic in relapsed or refractory AML [2] [US • 14 Apr 2026]

https://www.roswellpark.org/newsroom/202604-roswell-park-launches-exclusive-cd83-car-t-cell-clinical-trial-patients-relapsed-or
Context: Roswell Park Comprehensive Cancer Center launched an exclusive Phase 1 study in relapsed or refractory AML and has begun recruitment and first-patient treatment.
Key point: The CD83-targeted CAR-T approach is being assessed in patients for the first time, with safety as the primary goal.
Implication: Signals pipeline investment and modality expansion.

🩸 Faron, BEXMAB posts positive Phase II topline in higher-risk MDS [3] [EU • 15 Apr 2025]

https://faron.com/releases-and-publications/inside-information-faron-announces-positive-phase-ii-results-in-higher-risk-myelodysplastic-syndrome/
Context: BEXMAB is an open-label Phase I/II study of bexmarilimab plus azacitidine in aggressive hematologic malignancies, including higher-risk MDS.
Key point: Faron said the trial met its primary endpoint in treatment-resistant higher-risk MDS, with the combination remaining well tolerated.
Implication: May influence prescriber choice and payer reviews pending full data.

🧪 CERo, CER-1236 expands into MDS and myelofibrosis [4] [US • 14 Apr 2026]

https://www.cero.bio/press-release?storyId=5183103994740731
Context: CERo Therapeutics dosed the third patient in Cohort 2, sixth overall, in its first-in-human Phase 1/1b study in hematologic malignancies.
Key point: CER-1236 expanded from an AML-focused study population to include transfusion-dependent MDS, high-risk MDS, and post-JAK inhibitor myelofibrosis.
Implication: Signals pipeline investment and modality expansion.

👧 BioOra, Cincinnati Children’s partner on Atla-cel in pediatric B-ALL [5] [New Zealand/US • 14 Apr 2026]

https://bioora.com/our-stories/bioora-and-cincinnati-childrens-hospital-medical-center-partner-to-advance-next-generation-car-t-therapy-for-children-with-leukaemia
Context: Atla-cel (BioOra, atlacabtagene autoleucel) is a third-generation CD19-directed CAR-T therapy being advanced for children and adolescents with relapsed or refractory B-ALL.
Key point: BioOra and Cincinnati Children’s announced a strategic partnership to lead a global pediatric clinical program for Atla-cel.
Implication: Signals pipeline investment and modality expansion.

💼 Lilly, Jaypirca adds Phase 3 PFS win in previously treated CLL/SLL [6] [US • 13 Apr 2026]

https://investor.lilly.com/news-releases/news-release-details/lillys-jaypirca-pirtobrutinib-significantly-extended-progression
Context: BRUIN CLL-322 randomized 639 previously treated CLL/SLL patients to pirtobrutinib plus venetoclax and rituximab, or venetoclax and rituximab alone.
Key point: Lilly said the study met its primary endpoint, showing statistically significant and clinically meaningful progression-free survival improvement.
Implication: May influence prescriber choice and payer reviews pending full data.

🔬 Natera, Allogene report interim ALPHA3 signal for cema-cel in LBCL [7] [13 Apr 2026]

https://www.natera.com/company/news/natera-highlights-positive-interim-futility-analysis-from-allogene-therapeutics-mrd-guided-alpha3-trial-in-large-b-cell-lymphoma/
Context: ALPHA3 is a registrational, MRD-guided randomized controlled trial in first-line consolidation LBCL using Natera’s CLARITY assay to identify MRD-positive patients.
Key point: The interim futility analysis showed MRD clearance in 58.3% of cema-cel-treated MRD-positive patients and a median ctDNA decrease at Day 45 versus observation.
Implication: Could inform practice and payer discussions; interpretation depends on study design and confounding control.

🧫 Alethio, ATX-011 unveiled for essential thrombocythemia [8] [UK • 16 Apr 2026]

https://alethiotherapeutics.com/alethio-therapeutics-unveils-atx-011-a-breakthrough-mutation-agnostic-antibody-for-treating-essential-thrombocythemia-a-c-2b-market/
Context: Alethio Therapeutics presented ATX-011 as a mutation-agnostic antibody for essential thrombocythemia and appointed Steve R. Coats as chief development officer.
Key point: The company said ATX-011 showed rapid platelet lowering in non-human primates and is targeting IND submission in Q1 2027.
Implication: Signals pipeline investment and modality expansion.

Why it matters

Hematology news flow this week spans regulatory progress, first-in-human cell therapy, pediatric expansion, and late-stage readouts.
Multiple companies are positioning assets around unmet-need populations, including post-multi-line myeloma, relapsed AML, high-risk MDS, and MRD-positive lymphoma.
CAR-T development remains a major theme, across autologous, allogeneic, adult, and pediatric settings.
Several updates are topline or company-reported, so durability, subgroup detail, and peer-reviewed or congress data remain important next steps.

📚 View the full Hematology archive on our research hub page.

🎯 Catch up on the Top Hematology news from the past two weeks, curated by the LucidQuest team.

🎬 Watch on YouTube.

🚀 Accelerate your success. Contact us now

📂 Explore our case studies. See examples of our work.

💡 Read our insights. Learn from our latest reports and analysis

🧰 See our full range of services. Discover how we can help you.

FAQ

What changed for OPN-6602 at Opna Bio?

Opna Bio said FDA granted Fast Track designation to OPN-6602 for relapsed/refractory multiple myeloma after at least four prior lines of therapy. The asset remains in Phase 1. [1]

What is notable about Roswell Park’s CD83 CAR-T trial?

Roswell Park said this is the first clinical assessment of its CD83-targeted CAR-T approach in relapsed or refractory AML. The study is Phase 1 and primarily focused on safety. [2]

What did Faron report from BEXMAB?

Faron said BEXMAB met its primary endpoint in treatment-resistant higher-risk MDS and that bexmarilimab plus azacitidine remained well tolerated. The company said full data were submitted to the 2025 ASCO Annual Meeting. [3]

What is new in CERo’s CER-1236 program?

CERo said it dosed the sixth patient overall and expanded enrollment into MDS and myelofibrosis after early safety and pharmacology observations in the ongoing Phase 1 study. [4]

Why does the BioOra and Cincinnati Children’s partnership matter?

The collaboration moves Atla-cel into pediatric relapsed or refractory B-ALL, with Cincinnati Children’s leading the proposed global program. The source ties the rationale to adult data showing reduced neurotoxicity signals. [5]

What did Lilly report in BRUIN CLL-322?

Lilly said Jaypirca (pirtobrutinib) plus venetoclax and rituximab improved progression-free survival versus venetoclax and rituximab in previously treated CLL/SLL. Overall survival was not mature at the time of analysis. [6]

Why is ALPHA3 important for Natera and Allogene?

ALPHA3 is described as the first MRD-guided randomized controlled trial in LBCL. The interim analysis suggests cema-cel may clear residual molecular disease in a subset of MRD-positive patients. [7]

What is Alethio claiming for ATX-011?

Alethio presented ATX-011 as a preclinical, mutation-agnostic antibody for essential thrombocythemia, supported by non-human primate data and a stated goal of IND submission in Q1 2027. [8]

Entities / Keywords

Opna Bio, OPN-6602, EP300/CBP inhibitor, multiple myeloma, MM, Fast Track
Roswell Park Comprehensive Cancer Center, CD83 CAR-T, acute myeloid leukemia, AML
Faron Pharmaceuticals, bexmarilimab, BEXMAB, azacitidine, higher-risk myelodysplastic syndrome, HR-MDS
CERo Therapeutics, CER-1236, CER-T, AML, MDS, myelofibrosis, MF
BioOra, Cincinnati Children’s Hospital Medical Center, Atla-cel, atlacabtagene autoleucel, pediatric B-ALL, CD19 CAR-T
Eli Lilly, Jaypirca, pirtobrutinib, BRUIN CLL-322, chronic lymphocytic leukemia, small lymphocytic lymphoma, CLL/SLL
Natera, Allogene Therapeutics, ALPHA3, cema-cel, large B-cell lymphoma, LBCL, molecular residual disease, MRD, ctDNA, CLARITY
Alethio Therapeutics, ATX-011, essential thrombocythemia, ET, mutation-agnostic antibody, IND